IDNA:NYE-iShares Genomics Immunology and Healthcare ETF (USD)

ETF | Health |

Last Closing

USD 24.5

Change

0.00 (0.00)%

Market Cap

USD 0.14B

Volume

0.07M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

The fund generally will invest at least 80% of its assets in the component securities of the index and in investments that have economic characteristics that are substantially identical to the component securities of the index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. The index is composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology and bioengineering. -null-.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-03 )

ETFs Containing IDNA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 6.48% 62% D 54% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.48% 62% D 54% F
Trailing 12 Months  
Capital Gain 25.91% 86% B+ 72% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 25.91% 86% B+ 72% C
Trailing 5 Years  
Capital Gain -8.06% 48% F 44% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -8.06% 48% F 45% F
Average Annual (5 Year Horizon)  
Capital Gain -2.54% 5% F 23% F
Dividend Return -2.05% 5% F 14% F
Total Return 0.49% 53% F 12% F
Risk Return Profile  
Volatility (Standard Deviation) 35.06% 14% F 28% F
Risk Adjusted Return -5.84% 5% F 19% F
Market Capitalization 0.14B 60% D- 32% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.